1173523-52-8Relevant academic research and scientific papers
Potential CRF1R PET imaging agents: 1-Fluoroalkylsubstituted 5-halo-3-(arylamino)pyrazin-2(1H)-ones
Denhart, Derek J.,Zuev, Dmitry,Ditta, Jonathan L.,Hartz, Richard A.,Ahuja, Vijay T.,Mattson, Ronald J.,Huang, Hong,Mattson, Gail K.,Zueva, Larisa,Nielsen, Julia M.,Kozlowski, Edward S.,Lodge, Nicholas J.,Bronson, Joanne J.,MacOr, John E.
, p. 2052 - 2055 (2013/04/24)
A series of pyrazinones were prepared and evaluated as potential CRF 1R PET imaging agents. Optimization of their CRF1R binding potencies and octanol-phosphate buffer phase distribution coefficients are discussed herein.
Synthesis, structure-activity relationships, and in vivo evaluation of N3-phenylpyrazinones as novel corticotropin-releasing factor-1 (CRF1) receptor antagonists
Hartz, Richard A.,Ahuja, Vijay T.,Arvanitis, Argyrios G.,Rafalski, Maria,Yue, Eddy W.,Denhart, Derek J.,Schmitz, William D.,Ditta, Jonathan L.,Deskus, Jeffrey A.,Brenner, Allison B.,Hobbs, Frank W.,Payne, Joseph,Lelas, Snjezana,Li, Yu-Wen,Molski, Thaddeus F.,Mattson, Gail K.,Peng, Yong,Wong, Harvey,Grace, James E.,Lentz, Kimberley A.,Qian-Cutrone, Jingfang,Zhuo, Xiaoliang,Shu, Yue-Zhong,Lodge, Nicholas J.,Zaczek, Robert,Combs, Andrew P.,Olson, Richard E.,Bronson, Joanne J.,Mattson, Ronald J.,Macor, John E.
experimental part, p. 4173 - 4191 (2010/02/17)
Evidence suggests that corticotropin-releasing factor-1 (CRF1) receptor antagonistsmay offer therapeutic potential for the treatment of diseases associated with elevated levels of CRF such as anxiety and depression. A pyrazinone-based chemotype
